Novartis’s Zykadia ASCENDs First-Line NSCLC Heights But Roche’s Alecensa Gives Chase

Novartis’s anticancer Zykadia is catching up its rival, Pfizer’s Xalkori, by showing a benefit when used first line in the Phase III ASCEND-4 study in NSCLC, but must still look over its shoulder at Roche’s Alecensa.